NEW YORK (GenomeWeb News) – Global non-profit health advocacy organization Unitaid said today that its board has approved $30 million in funding to increase access to Cepheid's Xpert MTB/RIF diagnostic test for multi-drug-resistant tuberculosis in resource-poor areas of the world.

Under the agreement between Unitaid, the US Agency for International Development, and the Bill & Melinda Gates Foundation, Cepheid is expected to reduce the price of its Xpert MTB/RIF diagnostic cartridges to $10 from the current compassionate pricing of approximately $17, Unitaid said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.